Published on May 18, 2026
The EU Artificial Intelligence Act (EU AI Act) has fundamentally transformed the regulatory environment for artificial intelligence (AI) throughout Europe, with healthcare experiencing the most notable impact.
The EU AI Act: What It Means for Pharma, MedTech, and the Future of Healthcare
The EU AI Act came into effect in 2024 and is the first comprehensive legal framework worldwide for AI.1 Aimed at making AI safe, transparent, and trustworthy, it establishes a risk-based regulatory approach that influences how AI is developed and used within the healthcare sector.2,3 For pharmaceutical companies and medical device manufacturers, the Act functions not only as a compliance obligation but also as a catalyst for redefining digital innovation. Since its launch, the healthcare industry has been progressively implementing it, with high-risk AI requirements expected to come into effect from 2027.
Understanding the EU AI Act
At its core, the Act classifies AI systems into four categories:
Healthcare technologies are predominantly classified as high risk due to their significant potential impact on patient outcomes. The Act complements existing EU health legislation rather than replacing it.
Why Healthcare Is Uniquely Impacted
Medical Devices and SaMD Are Automatically High Risk
Any AI system integrated into a medical device or an in vitro diagnostic device is considered high-risk. This includes: diagnostic imaging AI, clinical decision support tools, remote monitoring algorithms and software as a Medical Device (SaMD). Manufacturers are now required to comply with both the MDR/IVDR and the AI Act, creating a dual regulatory pathway that demands more rigorous documentation, testing, and oversight.
Pharma Is Affected in Targeted Ways
Pharmaceutical companies have fewer direct obligations; however, several areas are still covered by the Act. These include AI used in clinical trials, AI supporting benefit–risk assessments, Patient facing digital therapeutics and AI used in pharmacovigilance or safety monitoring. Research-only AI is largely exempt; however, once an AI system affects patient care or regulatory filings, the Act applies.
Key Requirements for High Risk Healthcare AI
High-risk systems are required to comply with strict obligations, such as:
For MedTech companies, this involves integrating AI-specific controls into their current quality management systems.
Implications for the Healthcare Sector
The healthcare sector needs to consider several factors that could impact product development.
Stronger Data Governance: Healthcare AI must demonstrate data accuracy, bias mitigation, traceability and security and privacy protections. This elevates the standards for datasets employed in model training and validation.
Longer Development Timelines: More comprehensive testing and documentation could lengthen development timelines, particularly for AI enabled medical devices. Organisations will have to allocate resources to data governance teams, algorithmic auditing and model explainability tools.
Regulatory expertise: Non-EU companies deploying AI systems in the EU market must comply with the regulations, thereby turning the Act into a de facto global standard.
How Healthcare Organisations Can Prepare
To maintain a competitive edge, companies need to:
Although it introduces additional regulatory requirements, it provides several benefits, including harmonisation of EU-wide standards, increased investor and patient trust, clear market access rules, and global regulatory influence. Ultimately, the framework should help to accelerate the adoption of trustworthy medical AI across Europe.
Join our new training course, The 2024 EU (European Union) AI Act Training Course and learn how healthcare organisations are proactively planning to maintain competitiveness and maximise opportunities.
References